Post by Jonathan Royce

Merck Life Science's $11.3 billion bid for Bio-Techne clearly demonstrates how much value remains in the immunoassay market. 📈 The two companies' portfolios complement each other nicely: Merck already has a great platform of immunoassay solutions and now they add Bio-Techne's cytokine and antibody portfolio, ProteinSimple, a Bio-Techne brand's automated protein analysis tools, and their spatial biology positioning. What I'll be watching is how quickly the combined organization can actually integrate these capabilities, and whether that opens or closes doors for the smaller innovators working in the same space. Big consolidation creates interesting turbulence. 😰 https://lnkd.in/gKpq4sP4 #lifesciences #immunoassay #mergers #biotech